A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC
Abstract
Clinical benefit from first-line PD-1 inhibitor plus chemotherapy in advanced ESCC remains heterogeneous, and PD-L1 alone provides limited stratification. We evaluated plasma lncRNA RIME as a potential biomarker for stratifying first-line treatment outcomes in a multicenter cohort of patients with advanced ESCC. In the chemotherapy plus PD-1 inhibitor group, RIME-low was associated with higher ORR and better PFS/OS, whereas RIME-high was associated with poorer outcomes. Joint RIME/PD-L1 assessment further distinguished clinical benefit. Nested-model analyses showed that RIME provided non-redundant outcome information beyond PD-L1, and treatment-by-RIME interactions supported an exploratory predictive signal for ORR and PFS. Overall, plasma RIME was associated with outcome stratification and represents a potential predictive biomarker for immunochemotherapy benefit in ESCC.
Related
- Multimodal Immune Profile Score (IPS) as a Pan-Cancer Biomarker for Stratifying Outcomes of Immune Checkpoint Inhibitor Benefit in Microsatellite Stable Colorectal Cancer and Rare Solid Tumors
- Plasma cell-free RNA ITGB3 is associated with long-term clinical benefit in patients with non-small cell lung cancer receiving immunochemotherapy.
- Definitive radiotherapy versus surgery after neoadjuvant immunochemotherapy for locally advanced esophageal squamous cell carcinoma: a propensity score-matched study of efficacy and safety
- Association of trilaciclib use with hematologic outcomes during perioperative immunochemotherapy in resectable esophageal squamous cell carcinoma: a prospective observational cohort study
- Barriers to Biomarker-Guided Advanced Breast Cancer Care in India: Diagnostic, Economic, and Implementation Challenges
BibTeX
@article{liu2026biomarker,
title = {{A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC}},
author = {Jia Liu and Rui-Qi Ren and Ye He and Qi-Hua Zhang and Xiao-Min Zhang and Xiao-Jing Luo and Yu-Zhe Cao and Qi-Nian Wu and Hui-Yan Luo},
journal = {iScience},
year = {2026},
month = oct,
doi = {10.1016/j.isci.2026.117995},
url = {https://www.cell.com/iscience/fulltext/S2589-0042(26)03378-X},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A biomarker analysis of plasma RIME and PD-L1 for stratifying first-line immunochemotherapy outcomes in advanced ESCC
AU - Jia Liu
AU - Rui-Qi Ren
AU - Ye He
AU - Qi-Hua Zhang
AU - Xiao-Min Zhang
AU - Xiao-Jing Luo
AU - Yu-Zhe Cao
AU - Qi-Nian Wu
AU - Hui-Yan Luo
PY - 2026
DA - 2026/10/23
JO - iScience
DO - 10.1016/j.isci.2026.117995
UR - https://www.cell.com/iscience/fulltext/S2589-0042(26)03378-X
AB - Clinical benefit from first-line PD-1 inhibitor plus chemotherapy in advanced ESCC remains heterogeneous, and PD-L1 alone provides limited stratification. We evaluated plasma lncRNA RIME as a potential biomarker for stratifying first-line treatment outcomes in a multicenter cohort of patients with advanced ESCC. In the chemotherapy plus PD-1 inhibitor group, RIME-low was associated with higher ORR and better PFS/OS, whereas RIME-high was associated with poorer outcomes. Joint RIME/PD-L1 assessment further distinguished clinical benefit. Nested-model analyses showed that RIME provided non-redundant outcome information beyond PD-L1, and treatment-by-RIME interactions supported an exploratory predictive signal for ORR and PFS. Overall, plasma RIME was associated with outcome stratification and represents a potential predictive biomarker for immunochemotherapy benefit in ESCC.
SN - 2589-0042
ER -